Read by QxMD icon Read

Hematological Oncology

Keisuke Kawamoto, Takaharu Suzuki, Takuya Kasami, Maiko Kiryu, Hirohito Sone, Hiroaki Miyoshi, Koichi Ohshima, Jun Takizawa
No abstract text is available yet for this article.
November 5, 2018: Hematological Oncology
Renata Dos Santos Almeida, Matheus Costa E Silva, Luiz Lehmann Coutinho, Renan Garcia Gomes, Francisco Pedrosa, Juliana Doblas Massaro, Eduardo Antônio Donadi, Norma Lucena-Silva
MicroRNAs (miRNAs) play a critical role on biological and cellular processes, the search for functional markers may be of importance for differential diagnosis, prognosis and development of new therapeutic regimens. In this context, we evaluated the bone marrow miRNA profile of Brazilian children exhibiting T or B cell acute lymphoblastic leukemia (T-ALL or B-ALL), using massive parallel sequencing, using the HiSeq 2500 platform (Illumina). The differential expression analysis was conducted considering a leave-one-out approach and FDR ≤ 0...
November 4, 2018: Hematological Oncology
Takaaki Konuma, Yoshimitsu Shimomura, Yukiyasu Ozawa, Yasunori Ueda, Naoyuki Uchida, Makoto Onizuka, Megumi Akiyama, Takehiko Mori, Hirohisa Nakamae, Yuju Ohno, Souichi Shiratori, Yasushi Onishi, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Ken Ishiyama
To reduce post-transplant relapse, acute myeloid leukemia (AML) type remission induction chemotherapy has been attempted to reduce disease burden before allogeneic hematopoietic cell transplantation (HCT) in patients with advanced myelodysplastic syndrome (MDS). However, the efficacy of induction chemotherapy before HCT is unclear. We retrospectively analyzed the Japanese registration data of 605 adult patients, who had received allogeneic HCT for advanced MDS between 2001 and 2016, to compare the post-transplant relapse between patients who received induction chemotherapy followed by allogeneic HCT and those who received upfront HCT...
October 29, 2018: Hematological Oncology
Derek T Cawley, Joseph Butler, Adam Benton, Farhaan Altaf, Kia Rezajooi, Charalampia Kyriakou, Susanne Selvadurai, Sean Molloy
Discuss the relevant literature on surgical and non-surgical treatments for multiple myeloma (MM) and their complementary effects on overall treatment. Existing surgical algorithms designed for neoplasia of the spine may not suit the management of spinal myeloma. Less than a fifth of metastatic, including myelomatous lesions occur in the cervical spine but have a poorer prognosis and surgery in this area carries a higher morbidity. With the advances of chemotherapy, early access to radiotherapy, early orthosis management and high definition imaging including CT and MRI, surgical indications in MM have changed...
October 17, 2018: Hematological Oncology
Domenico Albano, Giovanni Bosio, Luca Camoni, Mirko Farina, Alessandro Re, Alessandra Tucci, Raffaele Giubbini, Francesco Bertagna
Mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent lymphoma with good prognosis and variable fluorine-18 fluorodeoxyglucose (18 F-FDG) avidity. Many possible prognostic factors have been investigated with controversial results, but the possible prognostic role of 18 F-FDG positron emission tomography/computed tomography (PET/CT) remains unclear. Our aim was to evaluate the prognostic impact of qualitative and semiquantitative baseline PET/CT parameters on outcome of MALT lymphoma. We retrospectively enrolled 161 patients with histologically confirmed MALT lymphoma who underwent 18 F-FDG PET/CT before any treatment...
October 9, 2018: Hematological Oncology
Francesca Caccuri, Elena Muraro, Annunziata Gloghini, Ombretta Turriziani, Mara Riminucci, Cinzia Giagulli, Katy Mastorci, Damiana Antonia Fae', Simona Fiorentini, Antonino Carbone, Arnaldo Caruso, Riccardo Dolcetti
Despite antiretroviral therapy, HIV+ individuals still have increased risk to develop lymphomas, including marginal zone lymphomas, suggesting that factors other than HIV-related immunosuppression are probably acting as lymphomagenic factors in the HIV setting. The possible pathogenic involvement of HIV p17 protein variants was investigated in a particularly informative case of HIV-related splenic marginal zone lymphoma, who was negative for oncogenic virus infections, thus allowing us to assess the possible direct contribution of these HIV-encoded proteins to lymphomagenesis...
September 27, 2018: Hematological Oncology
Alon Rozental, Anat Gafter-Gvili, Liat Vidal, Pia Raanani, Ronit Gurion
Randomized trials of maintenance therapy (MT) in diffuse large B cell lymphoma (DLBCL) are inconclusive regarding its effect on overall survival (OS) and disease control. We aimed to examine the efficacy and safety of MT in this meta-analysis. Systematic review and meta-analysis of randomized controlled trials comparing MT with observation or placebo, in patients with DLBCL, who achieved complete response (CR) or partial response (PR) after first-line chemotherapy with or without rituximab. Primary outcome was OS...
September 14, 2018: Hematological Oncology
Dai Chihara, Shannon Wong, Tatyana Feldman, Michelle A Fanale, Larysa Sanchez, Joseph M Connors, Kerry J Savage, Yasuhiro Oki
Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate that is highly effective in patients with relapsed/refractory anaplastic large cell lymphoma (ALCL). However, survival outcomes following suboptimal response or subsequent relapse are not well known. We conducted a multicenter study analyzing outcomes of patients with relapsed/refractory ALCL who have received BV with a secondary focus on survival after progression following BV. A total of 56 patients were treated with BV for relapsed or refractory ALCL...
September 12, 2018: Hematological Oncology
Alessandra Tedeschi, Concetta Conticello, Rita Rizzi, Giulia Benevolo, Luca Laurenti, Maria Teresa Petrucci, Francesco Zaja, Marzia Varettoni
The finding of an IgM monoclonal gammopathy often represents a diagnostic challenge. In fact, there are many pathological disorders associated with this condition, each of which has distinctive characteristics and requires specific clinical, instrumental, and laboratory assessments to set the appropriate treatment. This review has two aims. Firstly, to provide a framework of the broad spectrum of IgM-associated disorders: (1) monoclonal gammopathy of undetermined significance (MGUS); (2) Waldenström macroglobulinemia (WM); (3) IgM-related disorders (among which hyperviscosity syndrome, light chain amyloidosis, cold agglutinin disease, cryoglobulinaemia, IgM neuropathy, Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes (POEMS) syndrome, Castleman disease); (4) IgM-secreting multiple myeloma (IgM-MM); and (5) other lymphoproliferative disorders which may be associated with IgM (such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and B-cell non Hodgkin lymphoma)...
September 7, 2018: Hematological Oncology
Antonio Cuneo, Giovanni Barosi, Romano Danesi, Stefano Fagiuoli, Paolo Ghia, Alfredo Marzano, Marco Montillo, Venerino Poletti, Pierluigi Viale, Pier Luigi Zinzani
The introduction of new therapeutic agents in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), including the new kinase inhibitor idelalisib, has changed the therapeutic landscape of these diseases. However, the use of idelalisib is associated with a peculiar profile of side effects, which require an optimization of the current approach to prophylaxis and supportive treatment. Moving from the recognition that the abovementioned issue represents an unmet need in CLL and FL, a multidisciplinary panel of experts was convened to produce a consensus document aiming to provide practical recommendations for the management of the side effects during idelalisib therapy for CLL and FL...
September 5, 2018: Hematological Oncology
Tetsuhiro Kasamatsu, Shuji Ozaki, Takayuki Saitoh, Jun Konishi, Kazutaka Sunami, Mitsuhiro Itagaki, Hideki Asaoku, Takaaki Cho, Hiroshi Handa, Shotaro Hagiwara, Toshio Wakayama, Akiko Negoro, Naoki Takezako, Naoko Harada, Yoshiaki Kuroda, Chiaki Nakaseko, Takaaki Miyake, Nobumasa Inoue, Hiroyuki Hata, Chihiro Shimazaki, Tatsuharu Ohno, Junya Kuroda, Tohru Murayama, Takahiro Kobayashi, Masahiro Abe, Tadao Ishida, Eiich Nagura, Kazuyuki Shimizu
The international staging system (ISS) is the most commonly used risk-stratification system for patients with multiple myeloma (MM) and is determined by serum albumin and β2-microglobulin levels. In the two determinants, β2-microglobulin levels are frequently observed to be elevated in patients with myeloma, particularly in those with renal impairment. In comparison with patients with intact immunoglobulin myeloma, patients with LC myeloma do not necessarily show decreased levels of serum albumin. The clinical impact of ISS in patients with LCMM, in particular the distinction between ISS I and II, may be complicated due to non-decreased levels of serum albumin in both stages...
September 3, 2018: Hematological Oncology
Koji Kato, Naokuni Uike, Atsushi Wake, Makoto Yoshimitsu, Tomomi Tobai, Yasushi Sawayama, Yoshifusa Takatsuka, Takahiro Fukuda, Naoyuki Uchida, Tetsuya Eto, Yasuhiro Nakashima, Tadakazu Kondo, Jun Taguchi, Toshihiro Miyamoto, Hirohisa Nakamae, Tatsuo Ichinohe, Koji Kato, Ritsuro Suzuki, Atae Utsunomiya
Treatment options for patients with adult T cell leukemia/lymphoma (ATLL) who have relapsed disease after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are limited. To clarify which patients with ATLL are likely to benefit from these treatment options and to define patient populations for novel treatments, we performed a nationwide retrospective analysis of 252 Japanese patients who had relapsed ATLL after allo-HSCT. Some long-term survivors remained after tapering and withdrawal of immunosuppressive agents...
September 1, 2018: Hematological Oncology
Christopher B Benton, Kelly S Chien, Ayalew Tefferi, Jose Rodriguez, Farhad Ravandi, Naval Daver, Elias Jabbour, Nitin Jain, Yesid Alvarado, Monica Kwari, Sherry Pierce, Abhishek Maiti, Marisa Hornbaker, Margarida A Santos, Sara Martinez, Mariano Siguero, Darci Zblewski, Aref Al-Kali, William J Hogan, Hagop Kantarjian, Animesh Pardanani, Guillermo Garcia-Manero
Trabectedin is an FDA-approved DNA minor groove binder (MGB) that has activity against translocation-associated sarcomas. Lurbinectedin is a next-generation MGB with pre-clinical activity against myeloid leukemia cells. A dose-finding phase 1 clinical trial was performed in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with further assessment of safety and tolerability. Forty-two patients with relapsed/refractory AML/MDS received lurbinectedin administered as a 1-hour intravenous infusion in a 3+3 study design...
August 28, 2018: Hematological Oncology
Heimo Lagler, Barbara Kiesewetter, Werner Dolak, Markus Obermueller, Ingrid Simonitsch-Klupp, Julius Lukas, Ortrun Neuper, Wolfgang W Lamm, Marius E Mayerhoefer, Markus Raderer
The macrolide clarithromycin has been reported as active for therapy of mucosa associated lymphoid tissue (MALT) lymphoma. Pharmacokinetic properties, however, require continuous daily intake over a prolonged period of time. As the macrolide azithromycin is characterized by a long half-life as well as potential antineoplastic activity in vitro, we have performed a phase II trial of long-term once-weekly oral azithromycin for treatment of MALT lymphoma. In a 2-stage-design, 16 patients (10 f/6 m) with histologically verified and measurable MALT lymphoma were included in the first phase of the trial, which could be expanded to a maximum of 46 patients depending on remissions in the first phase...
August 28, 2018: Hematological Oncology
Patrizia Ciammella, Stefano Luminari, Luca Arcaini, Andrea Riccardo Filippi
Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoproliferative disorders. Treatment strategies for FL may include several therapeutic choices, ranging from a "watchful waiting" approach to stem cell transplantation, mostly depending on staging, age, risk factors, and disease burden at diagnosis. The high radiosensitivity of FL compared with other solid tumors has been known since the beginning of radiotherapy treatment in lymphoma patients. Doses of 24 to 40 Gy were considered appropriate in first line curative treatment for localized disease (stages I-II), but several publications investigating low-dose radiotherapy (LDRT) of 4Gy (2 × 2Gy) reported an overall response rate surprisingly high...
August 26, 2018: Hematological Oncology
Lenka Sedlarikova, Bozena Bollova, Lenka Radova, Lucie Brozova, Jiri Jarkovsky, Martina Almasi, Miroslav Penka, Petr Kuglík, Viera Sandecká, Martin Stork, Ludek Pour, Sabina Sevcikova
Multiple myeloma is the second most common hematological malignancy characterized by focal lesions of malignant plasma cells in the bone marrow. These lesions contain subclones that directly influence survival of patients. Bone marrow biopsies are single-site biopsies and thus cannot contain all information about the tumor. In contrast, liquid biopsies analyze circulating cells and molecules that are secreted from all sites of the tumor. Long noncoding RNA molecules are one class of these molecules. We performed a two-phase biomarker study investigating lncRNA expression profiles in exosomes of peripheral blood serum of newly diagnosed multiple myeloma (MM) patients, monoclonal gammopathy of undetermined significance (MGUS) patients in comparison with healthy donors (HD)...
August 24, 2018: Hematological Oncology
Mingxiao Lang, Jingwei Yu, Xianhuo Wang, Zheng Song, Lanfang Li, Lihua Qiu, Huilai Zhang
Interstitial pneumonia (IP) is one of the potentially fatal adverse events for lymphoma patients undergoing immunochemotherapy. However, the risk factors and predictive markers remain unclear for this complication. This retrospective study aims to explore whether the change of absolute monocyte count (AMC) during immunochemotherapy is correlated with IP occurrence and progression. A total of 500 lymphoma patients receiving immunochemotherapy from 2014 to 2016 were enrolled in this investigation. Interstitial pneumonia was generally diagnosed as diffused pulmonary interstitial infiltrates on computed tomography images in conjunction with respiratory symptoms or pulmonary function test, which is also adopted as a diagnosing tool of IP in this study...
August 24, 2018: Hematological Oncology
Ana Jiménez-Ubieto, Carlos Grande, Dolores Caballero, Lucrecia Yáñez, Silvana Novelli, Miguel Teodoro Hernández-Garcia, María Manzanares, Reyes Arranz, José Javier Ferreiro, Sabela Bobillo, Santiago Mercadal, Andrea Galeo, Javier López Jiménez, José María Moraleda, Carlos Vallejo, Carmen Albo, Elena Pérez, Carmen Marrero, Laura Magnano, Luis Palomera, Isidro Jarque, Pilar Martínez-Sánchez, Alejandro Martín, Erika Coria, Armando López-Guillermo, Antonio Salar, Juan José Lahuerta
No abstract text is available yet for this article.
August 20, 2018: Hematological Oncology
Leo Sekine, Patrícia Klarmann Ziegelmann, Denise Manica, Carolina da Fonte Pithan, Monalisa Sosnoski, Vinicius Daudt Morais, Frederico Soares Falcetta, Mariana Rangel Ribeiro, Ana Paula Salazar, Rodrigo Antonini Ribeiro
Autologous transplantation continues to be the cornerstone of younger and fit multiple myeloma patients. It is known that frontline induction therapy before transplantation can influence post-transplant results. Therefore, best frontline treatment for transplant-eligible patients should be based on best available evidence to guide therapy. Furthermore, until now due to data scarcity, it was not possible to thoroughly compare lenalidomide to other regimens in this setting. We performed a systematic review and network (mixed treatment comparison) meta-analysis of 21 clinical trial publications, enrolling 6474 patients and comparing 11 different treatment frontline setting regimens regarding survival, response, and safety outcomes...
August 20, 2018: Hematological Oncology
Pavel Klener, Eva Fronkova, Marketa Kalinova, David Belada, Kristina Forsterova, Robert Pytlik, Petra Blahovcova, Martin Simkovic, David Salek, Heidi Mocikova, Vit Prochazka, Andrea Janikova, Martina Vaskova, Ester Mejstrikova, Roman Kodet, Jan Trka, Marek Trneny
Rituximab maintenance (RM) prolongs survival of elderly patients with mantle cell lymphoma (MCL). Persistent minimal residual disease (MRD) after induction repeatedly correlated with shorter progression-free survival (PFS). However, none of the published studies analyzed patients treated with RM. The main purpose was to analyze prognostic significance of MRD in the elderly patients with newly diagnosed MCL treated according to the recently published observational trial protocol (alternation of R-CHOP and R-cytarabine, 3 + 3 cycles, GovTrial number NCT03054883) at the centers that implemented RM...
August 20, 2018: Hematological Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"